Showing results (461-470 of 590) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging databaseJohn F Thompson, Seng-Jaw Soong, Charles M Balch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020Wendy R Cornett, Linda M McCall, Rebecca P Petersen, et al.
Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Annals of Surgical Oncology|March 16, 2026
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Surgical Oncology|February 18, 2014
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patientsCharles M Balch, John F Thompson, Jeffrey E Gershenwald, et al.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Pageof 59